Testing drug choice with patient tumor models for early bladder cancer
Tests bladder drugs chosen with patient-derived tumor models in low-grade bladder cancer.
Plain-language title generated from the registry record
Registry title: Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Key facts
- Where
- Bern and Biel, SwitzerlandSee the 2 sites
- Phase
- Phase 2
Where in Switzerland
- Lindenhofspital, Klinik für UrologieBern, SwitzerlandNo longer taking part
- Spitalzentrum Biel, Klinik für UrologieBiel, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Centre Biel/Bienne
- Trial code
- NCT06227065
- Record updated
- 18 September 2026
- Original description
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.Read full original descriptionShow less
POLO-Trial. Precise Neoadjuvant Chemoresection of Low-grade NMIBC Guided by Drug Sceens in Patient-derived Or-ganoids. An Open-label, Phase II Trial.
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.
Inclusion: Signed Informed Consent Form; Age ≥ 18 years; Primary or recurrent NMIBC suspected to be low-grade or maximum G2 with a negative urine cytology.
Exclusion: Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol as judged by the investigator; Severe infection within 4 weeks prior to the date of the patient's informed consent signature; Pregnancy or nursing. Female subject of childbearing potential (defined as premenopausal women who have not undergone surgical sterilization and are sexually active with a male part-ner) must have a negative urine pregnancy test at screening; Concomitant participation in another interventional clinical trial with an active treatment within 4 weeks prior to the date of the patient's informed consent signature and during the current trial; Anticoagulation other than acetylsalicylic acid; Contraindication for frequent catheterization; Female subject of childbearing potential who is unwilling to use effective contraception method(s) from the start of the intravesical instillation with the IMP until six months after the last instillation; Male subject who is unwilling to use an effective contraception method from the start of the intravesical instillation with the IMP until four months after the last instillation; Vulnerable individual, e.g., individual incapable of judgement or currently incarcerated or oth-erwise institutionalized (prisoner), or refugee.